NASDAQ:VSTM - Nasdaq - US92337C2035 - Common Stock - Currency: USD
6.94
+0.25 (+3.74%)
The current stock price of VSTM is 6.94 USD. In the past month the price increased by 31.44%. In the past year, price decreased by -41.43%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 18.07 | 328.29B | ||
AMGN | AMGEN INC | 13.1 | 146.27B | ||
GILD | GILEAD SCIENCES INC | 12.68 | 122.21B | ||
VRTX | VERTEX PHARMACEUTICALS INC | N/A | 110.44B | ||
REGN | REGENERON PHARMACEUTICALS | 12.36 | 59.13B | ||
ARGX | ARGENX SE - ADR | 299.54 | 34.75B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 33.61B | ||
ONC | BEIGENE LTD-ADR | 5.88 | 25.43B | ||
BNTX | BIONTECH SE-ADR | N/A | 22.78B | ||
NTRA | NATERA INC | N/A | 22.10B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.31B | ||
BIIB | BIOGEN INC | 7.48 | 17.35B |
Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company is headquartered in Needham, Massachusetts and currently employs 78 full-time employees. The company went IPO on 2011-11-08. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.
VERASTEM INC
117 Kendrick Street, Suite 500
Needham MASSACHUSETTS 02494 US
CEO: Brian M. Stuglik
Employees: 78
Phone: 17812924200
The current stock price of VSTM is 6.94 USD. The price increased by 3.74% in the last trading session.
The exchange symbol of VERASTEM INC is VSTM and it is listed on the Nasdaq exchange.
VSTM stock is listed on the Nasdaq exchange.
15 analysts have analysed VSTM and the average price target is 13.64 USD. This implies a price increase of 96.58% is expected in the next year compared to the current price of 6.94. Check the VERASTEM INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
VERASTEM INC (VSTM) has a market capitalization of 357.34M USD. This makes VSTM a Small Cap stock.
VERASTEM INC (VSTM) currently has 78 employees.
VERASTEM INC (VSTM) has a support level at 6.52 and a resistance level at 7.51. Check the full technical report for a detailed analysis of VSTM support and resistance levels.
The Revenue of VERASTEM INC (VSTM) is expected to grow by 17.95% in the next year. Check the estimates tab for more information on the VSTM EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
VSTM does not pay a dividend.
VERASTEM INC (VSTM) will report earnings on 2025-08-06.
VERASTEM INC (VSTM) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.5).
The outstanding short interest for VERASTEM INC (VSTM) is 19.02% of its float. Check the ownership tab for more information on the VSTM short interest.
ChartMill assigns a technical rating of 6 / 10 to VSTM. When comparing the yearly performance of all stocks, VSTM is a bad performer in the overall market: 70.23% of all stocks are doing better.
ChartMill assigns a fundamental rating of 1 / 10 to VSTM. VSTM may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months VSTM reported a non-GAAP Earnings per Share(EPS) of -3.5. The EPS increased by 14.63% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -128.66% | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 85% to VSTM. The Buy consensus is the average rating of analysts ratings from 15 analysts.
For the next year, analysts expect an EPS growth of 30.11% and a revenue growth 17.95% for VSTM